Egis Pharmaceuticals PLC is one of the leading generic pharmaceutical companies in Central Eastern Europe with activities extending to every field of pharmaceutical production from research and development, through active ingredient and finished production to sales and marketing.
In the past one hundred years that have passed since the foundation of Egis in 1913, Egis has grown into an internationally renowned company with about 4000 employees worldwide.
Egis products are sold to 60 countries and 75 percent of its turnover derives from exports. Egis drugs acting on the cardiovascular, central nervous and respiratory systems account for almost three-quarters of our turnover and we are continuously open towards new areas. In 2013, Egis launched Europe’s first biosimilar monoclonal antibody and it is our strategic goal to become a key player in the biosimilar therapies’ segment.
Contact
Address: Ovocný trh 1096/8, Praha, Czech Republic
Phone number: +420 227 129 111
Homepage: http://www.egispraha.cz/
The latest pharma news from Central and Eastern Europe (CEE), including a new report on the disparities between the region’s healthcare systems and those of Western Europe; why US companies…
Roman Grunt, CEO of Quinta Analytica, gives us an overview of the activities of how the Czech firm has managed to attract customers across the country and beyond by positioning…
PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: Czech Republic is available for download now. Home to a USD 3.38 billion pharma market, one of Central and Eastern Europe’s…
Key stakeholders within the Czech medtech industry highlight how medical devices can improve efficiency and quality of care across the country’s healthcare landscape, why greater levels of collaboration are of…
Roman Samiec, general manager of Thuasne Czech Republic, introduces the company as a key competitor in the medical devices field, with their niche products addressing the unmet medical need in…
Miroslav Palát, president of CzechMed, the medical device association in the Czech Republic, and Jiří Pavlíček, who combines the responsibility of Chairman of the association and CEO of the medtech…
Pavla Nevolová, country head of EastHORN in the Czech Republic, shares the historical roots of the now multinational Czech CRO. Nevolová also shares her insights into the recent evolution of…
The Czech Republic boasts a solid clinical research infrastructure and a supportive regulatory environment, meaning that it stands out as one of Central and Eastern Europe’s top destinations for clinical…
In 1996 Jiří Žák, chairman & current CEO of FARMAK, borrowed half a billion Czech crowns to take over a state-owned producer of vitamins for which he had started working…
As one of the few pharma companies in the Czech Republic to offer products across the whole healthcare spectrum, including prescription drugs, generics, over-the-counter (OTC) treatments, and food supplements, the…
Roman Dusil, GM of Pierre Fabre Laboratories in the Czech Republic and Slovakia, shares how the Czech affiliate is ahead of Pierre Fabre’s global transformation of the convergence between the dermo-cosmetic…
Pharma industry stakeholders are generally quick to suggest that the Czech Republic is one of the most over-regulated markets in Europe, with new or innovative therapies facing significant delays before…
See our Cookie Privacy Policy Here
